ixekizumab
Trade name: taltz
mAbapproved
Approved
Mar 22, 2016
Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody. The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation. — Wikipedia
Clinical trial activity
58 trials · 33 clinical orgs · 1 marketing orgs
Phase 1
10
Phase 2
36
Phase 3
28
Phase 4
8
Earliest trial started Aug 1, 2009 (NCT00966875)
Timeline
Indications
Approved for
Studied for
- Arthritis · Phase 3
- Arthritis, Juvenile · Phase 3
- Arthritis, Psoriatic · Phase 4
- Arthritis, Rheumatoid · Phase 2
- Axial Spondyloarthritis · Phase 3
- Constriction, Pathologic · Phase 2
- COVID-19 · Phase 3
- Diabetes Mellitus, Type 1 · Phase 2
- Healthy Volunteers · Phase 1
- Lichen Planus · Early Phase 1
- Major Depressive Disorder · Phase 2
- Obesity · Phase 3
- Panuveitis · Phase 4
- Pemphigoid, Bullous · Phase 2
- Pityriasis Rubra Pilaris · Phase 2
- Pyoderma Gangrenosum · Phase 2
- Rheumatic Diseases · Phase 2
- Spondylitis, Ankylosing · Phase 3
- Substance Withdrawal Syndrome · Phase 3
- Uveitis, Anterior · Phase 4
- Uveitis, Intermediate · Phase 4
- Uveitis, Posterior · Phase 4
Mechanism of action
- Interleukin 17AINHIBITOR
IL17A inhibitor
Approval history
- approvedMar 22, 2016
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaIxekizumab ↗
- NCATSBTY153760O ↗
- ChEMBLCHEMBL1743034 ↗
Also known as
- ixekizumab
- ixekizumab
- ixekizumab
- ixekizumab
- ixekizumab
- ixekizumab
- ixekizumab
- ixekizumab
- ixekizumab
- ixekizumab (genetical recombination)
- ixekizumab (genetical recombination)
- ixekizumab (genetical recombination)
- ixekizumab (genetical recombination)
- ly2439821
- ly2439821
- ly2439821
- ly-2439821
- ly-2439821
- taltz
- taltz
- taltz
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07138898 | Phase 2 | Sep 30, 2025 | New York University |
| NCT07200986 | Phase 1 | Sep 17, 2025 | Celltrion |
| NCT06945107 | Phase 3 | May 27, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06811558 | N/A | Feb 1, 2025 | Zhejiang University |
| NCT06588283 | Phase 3 | Sep 30, 2024 | Eli Lilly |
| NCT06588296 | Phase 3 | Sep 24, 2024 | Eli Lilly |
| NCT06398106 | Phase 4 | Sep 1, 2024 | Ghent University, Katholieke Universiteit Leuven |
| NCT06374979 | Phase 2/Phase 3 (Phase 3) | Apr 30, 2024 | Zhejiang University |
| NCT05855967 | Phase 4 | Jun 27, 2023 | Eli Lilly |
| NCT05503875 | N/A | Jan 1, 2023 | Zhejiang University |
| NCT05309616 | Phase 2 | Nov 30, 2022 | Yale University |
| NCT06085079 | Phase 4 | Jun 1, 2022 | Eli Lilly, Harvard University |
| NCT05042635 | N/A | Oct 1, 2021 | Shanghai Skin Disease Hospital, Shanghai University of Traditional Chinese Medicine, Tongji University |
| NCT05030415 | Early Phase 1 (Phase 1) | Aug 31, 2021 | University of New Mexico |
| NCT04979910 | Phase 2 | Aug 27, 2021 | Icahn School of Medicine at Mount Sinai |
| NCT04589325 | Phase 2 | Feb 28, 2021 | Eli Lilly, Gothia Forum, Karolinska Institute, Statistika Consultoria Ltda, Vastra Gotaland Region |
| NCT04527380 | Phase 3 | Jan 12, 2021 | Eli Lilly |
| NCT04724629 | Phase 3 | Jan 5, 2021 | Conselho Nacional de Desenvolvimento Científico e Tecnológico, Duke University, Hospital das Clinicas da USP, Hospital e Maternidade Dr. Christóvão da Gama, Hospital Leforte Liberdade, SP, Brazil, Science Valley Research Institute, University of Sao Paulo |
| NCT04537689 | Phase 4 | Nov 16, 2020 | Singapore General Hospital, SingHealth Investigational Medicine Unit |
| NCT04610476 | Phase 3 | Oct 31, 2020 | University of Erlangen-Nuremberg |
Showing 20 of 58 trials
Page 1 / 3
Organizations
Research & Development (33)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 43 | 38 | 4 | 2009 |
| Zhejiang University | Academic/Hospital | 3 | 3 | 2 | 2023 |
| Ghent University | Academic/Hospital | 2 | 1 | 1 | 2020 |
| Katholieke Universiteit Leuven | Academic/Hospital | 2 | 0 | 1 | 2020 |
| Celltrion | For profit | 1 | 1 | 1 | 2025 |
| Conselho Nacional de Desenvolvimento Científico e Tecnológico | Government | 1 | 0 | 1 | 2021 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Gothia Forum | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Hospital das Clinicas da USP | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Hospital e Maternidade Dr. Christóvão da Gama | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Hospital Leforte Liberdade, SP, Brazil | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 1 | 1 | 1 | 2025 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2017 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Oregon Health and Science University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2020 |
33 organizations
Page 1 / 2